<DOC>
	<DOCNO>NCT00003385</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness combination chemotherapy consist liposomal doxorubicin , paclitaxel , carboplatin treat patient untreated ovarian , peritoneal , fallopian tube cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Untreated Ovarian , Peritoneal , Fallopian Tube Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose doxorubicin HCl liposome administer paclitaxel carboplatin patient previously untreated ovarian epithelial , peritoneal , fallopian tube cancer . - Determine toxicity treatment regimen patient . - Evaluate measurable disease patient treat regimen . OUTLINE : This dose-escalation study doxorubicin HCl liposome ( LipoDox ) . Patients receive LipoDox IV day 1 , carboplatin IV 3 hour day 1 22 , paclitaxel IV 1 hour day 1 , 8 , 15 , 22 , 29 , 36 . Treatment repeat every 42 day 4 course absence unacceptable toxicity disease progression . Cohorts 3-6 patient receive escalate dos LipoDox maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . An additional cohort 12 patient receive LipoDox MTD carboplatin paclitaxel . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : Approximately 48 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm previously untreated ovarian epithelial carcinoma , peritoneal carcinoma , fallopian tube carcinoma The following histologic epithelial cell type eligible : Serous adenocarcinoma Endometrioid adenocarcinoma Mucinous adenocarcinoma Undifferentiated carcinoma Clear cell adenocarcinoma Mixed epithelial carcinoma Transitional cell Malignant Brenner tumor Adenocarcinoma otherwise specify No 12 week since diagnosis No ovarian epithelial carcinoma low malignant potential ( borderline carcinoma ) PATIENT CHARACTERISTICS : Age : Not specify Performance status : GOG 02 Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm^3 Platelet count least 100,000/mm^3 Absolute granulocyte count least 1,500/mm^3 Hepatic : Bilirubin great 1.5 time normal SGOT/SGPT great 3 time normal Alkaline phosphatase great 3 time normal Gammaglutamyltransferase great 3 time normal No acute hepatitis Renal : Creatinine great 2.0 mg/dL OR Creatinine clearance great 50 mL/min Cardiovascular : LVEF normal MUGA No unstable angina No myocardial infarction within past 6 month Patients abnormal cardiac conduction ( e.g. , bundle branch block heart block ) eligible disease stable past 6 month Other : No septicemia severe infection No severe gastrointestinal bleeding No invasive malignancy within past 5 year except nonmelanoma skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy Surgery : Recovered recent prior surgery Other : No prior anticancer therapy would preclude study</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2003</verification_date>
	<keyword>stage I ovarian epithelial cancer</keyword>
	<keyword>stage II ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>ovarian undifferentiated adenocarcinoma</keyword>
	<keyword>ovarian mixed epithelial carcinoma</keyword>
	<keyword>ovarian serous cystadenocarcinoma</keyword>
	<keyword>ovarian mucinous cystadenocarcinoma</keyword>
	<keyword>ovarian endometrioid adenocarcinoma</keyword>
	<keyword>ovarian clear cell cystadenocarcinoma</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
	<keyword>Brenner tumor</keyword>
</DOC>